Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine

Journal of Child and Adolescent Psychopharmacology

Volumn 22, Issue 6, 2012, Pages 423-431

  Arcieri, Romano ^a   Germinario, Elena A P ^a   Bonati, Maurizio ^b   Masi, Gabriele ^c   Zuddas, Alessandro ^d   Vella, Stefano ^a   Chiarotti, Flavia ^a   Panei, Pietro ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c DEPARTMENT OF DEVELOPMENTAL NEUROSCIENCE   (Italy)

^d UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR EFFECT; CHILD; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART RATE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; QT PROLONGATION; SCHOOL CHILD;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; ITALY; MALE; METHYLPHENIDATE; PROPYLAMINES; PROSPECTIVE STUDIES; REGISTRIES;

EID: 84871226888     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2012.0014     Document Type: Article

References (25)

1. American Academy of Pediatrics: CoQI, Subcommittee on Attention-Deficit/Hyperactivity Disorder Clinical Practice Guideline: Diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 105:1158-1170, 2000.
2. Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ, Campbell WB, Haines DE, Kuck KH, Lerman BB, Miller DD, Shaeffer CW, Stevenson WG, Tomaselli GF, Antman EM, Smith SC Jr, Alpert JS, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Hiratzka LF, Hunt SA, Jacobs AK, Russell RO Jr, Priori SG, Blanc JJ, Budaj A, Burgos EF, Cowie M, Deckers JW, Garcia MA, Klein WW, Lekakis J, Lindahl B, Mazzotta G, Morais JC, Oto A, Smiseth O, Trappe HJ; European Society of Cardiology Committee, NASPE-Heart Rhythm Society: Guidelines for the management of patients with supraventricular arrhythmias. J Am Coll Cardiol 42:1493-1531, 2003.
3. Cheng JY, Chen RY, Ko JS, Ng EM: Efficacy and safety of atomoxetine for attention-deficit hyperactivity disorder in children and adolescents-meta- analysis and meta-regression analysis. Psychopharmacol 194:197-209, 2007. (Pubitemid 47457955)
4. Davignon A, Rautaharju P, Boiselle E, Soumis F, Megelas M, Choquette A: Normal ECG standards for infants and children. Pediatr Cardiol 1:123-131, 1979. (Pubitemid 10080075)
5. Elia J, Vetter VL. Cardiovascular effects of medications for the treatment of attention-deficit hyperactivity disorder: What is known and how should it influence prescribing in children? Pediatric Drugs 12:165-175, 2010.
6. EMEA: Elements recommended for inclusion in Summaries of Product Characteristics for methylphenidate-containing medicinal products authorized for the treatment of ADHD in children aged six years and above and adolescents. CHMP; January 22, 2009. Doc. Ref. EMEA/22315/2009. Available at www.ema.europa.eu/docs/en-GB/document-library/Referrals-document/ Methylphenidate-31/WC500011184.pdf.
7. Gelperin K, Brinker AD, Avigan MI: MedWatch reporting of death, sudden death, and cardiovascular events in association with stimulant used in the treatment of ADHD over a recent 5-years period. Available at www.cfsan.fda.gov/*frf/forum06/1-04.htm. Accessed July 3, 2006.
8. Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Döpfner M, Hamilton R, Hollis C, Holtmann M, Hulpke-Wette M, Lecendreux M, Rosenthal E, Rothenberger A, Santosh P, Sergeant J, Simonoff E, Sonuga-Barke E, Wong IC, Zuddas A, Steinhausen HC, Taylor E; European Guidelines Group: European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 20:17-37, 2011.
9. Hammerness P, Georgiopoulos A, Doyle RL, Utzinger L, Schillinger M, Martelon M, Brodziak K, Biederman J, Wilens TE: An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. J Child Adolesc Psychopharmacol 19:493-499, 2009a.
10. Hammerness P, Wilens T, Mick E, Spencer T, Doyle R, McCreary M, Becker J, Biederman J: Cardiovascular effects of longer-term, highdose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder. J Pediatr 155:84-89, 2009b.
11. Hammerness PG, Perrin JM, Shelley-Abrahamson R, Wilens TE: Cardiovascolar risk of stimulant treatment in pediatric attentiondeficit/hyperactivity disorder: Update and clinical recommendations. J Am Acad Child Adolesc Psychiatry 50:978-990, 2011.
12. Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Baker KD, Feldman PD, Gelowitz DL: Effect of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:919-927, 2006. (Pubitemid 44126866)
13. Panei P, Arcieri R, Vella S, Bonati M, Martini N, Zuddas A: Italian attention-deficit/hyperactivity disorder registry. Pediatrics 114:514, 2004.
14. Pliszka S, AACAP Work Group on Quality Issues: Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46:894-921, 2007.
15. Ritalin (methyphenidate) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2007.
16. Schachter HM, Pham B, King J, Langfor S, Moher D: How efficacious and safe is short-acting methylphenidate for treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 165:1475-1488, 2001. (Pubitemid 34060190)
17. Scheffler RM, Hinshaw SP, Modrek S, Levine P: The global market for ADHD medications. Health Aff 26:450-457, 2007.
18. Stiefel G, Besag FM: Cardiovascular effects of methylphenidate, amphetamines and atoxometine in the treatment of attention-deficit hyperactivity disorder. Drug Saf 33:821-842, 2010.
19. Strattera (atomoxetine) package insert. Indianapolis: Ely Lilly and Company, 2003.
20. Surawicz B, Childers R, Deal BJ, Gettes LS, Bailey JJ, Gorgels A, Hancock EW, Josephson M, Kligfield P, Kors JA, Macfarlane P, Mason JW, Mirvis DM, Okin P, Pahlm O, Rautaharju PM, van Herpen G, Wagner GS, Wellens H; American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; American College of Cardiology Foundation; Heart Rhythm Society: AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the Electrocardiogram Part III: Intraventricular conduction disturbances. Circulation 119:e235-e240, 2009.
21. Takahashi M, Takita Y, Yamazaki K, Hayashi T, Ichikawa H, Kambayashi Y, Koeda T, Oki J, Saito K, Takeshita K, Allen AJ: A randomized, double-blind, placebo-controlled study of atomoxetine in Japanese children and adolescents with attention-defcit/hyperactivity disorder. J Child Adolesc Psychopharmacol 19:341-350, 2009.
22. Thomas PE, Carlo WF, Decker JA, Cannon BC, Kertesz NJ, Friedman RA, Kim JJ: Impact to the American Heart Association scientific statement on screening electrocardiograms and stimulant medication. Arch Pediatr Adolesc Med 165:166-170, 2011.
23. Volkow ND, Wang GJ, Fowler JS, Molina PE, Logan J, Gatley SJ, Gifford A, Ding YS, Wong C, Pappas NR, Zhu W, Swanson JM: Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma. Psychopharmacol 166:264-270, 2003. (Pubitemid 36384773)
24. Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, Quintana H, Lipetz R, Michelson D, Heiligenstein J: Cardiovascular effects of atomoxetine in children, adolescents and adults. Drug Saf 26:729-740, 2003. (Pubitemid 36976134)
25. Wilens TE, Biederman J, Lerner M, Concerta Study Group: Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: Results from a one-year follow-up study Clin Psychopharmacol 24:36-41, 2004. (Pubitemid 38134164)